Amgen Reports P-III (DeLLphi-304) Trial Findings of Imdelltra for SCLC
Shots:
- Amgen has reported P-III (DeLLphi-304) trial data evaluating Imdelltra (tarlatamab-dlle) vs SoC CT (topotecan globally excl. Japan; lurbinectedin in the US, Canada, Australia, Singapore, Korea; & amrubicin in Japan) in SCLC pts who progressed on or after single line of Pt-based CT
- In the interim analysis, trial met its 1EP, with superior OS; full data to be presented at a future conference
- Imdelltra is an immunotherapy that targets DLL3 on cancer cells & CD3 on T cells, triggering the T cells to destroy DLL3-expressing SCLC cells
Ref: Amgen | Image: Amgen
Related News:- Amgen’s Uplizna Receives the US FDA’s Approval for Immunoglobulin G4-related Disease (IgG4-RD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
